Novel Modulators of LDL Metabolism

Period of Performance: 05/01/2015 - 04/30/2016


Phase 2 SBIR

Recipient Firm

Shifa Biomedical
Malvern, PA 19355
Principal Investigator


DESCRIPTION (provided by applicant): Heart disease is the leading cause of death for both men and women in the US, accounting for nearly 40% of all annual deaths. A high cholesterol level is well-known risk factors for heart disease. Although blood cholesterol can be lowered using a number of marketed drugs, of which statins are the leading drugs, only 38% of patients taking these drugs are achieving the low-density lipoprotein cholesterol goals set by the National Cholesterol Education Program (NCEP). Furthermore, patients with homozygous familial hypercholesterolemia who have markedly elevated cholesterol levels respond poorly to current drug therapy, and are at very high risk of premature cardiovascular disease. These and other patients will dramatically benefit from an aggressive treatment of hypercholesterolemia. The long-term goal of this work is to develop novel drugs for cholesterol lowering. Our therapeutic target is the protease proprotein convertase subtilisin-like kexin type 9 (PCSK9). PCSK9 controls the degradation of the LDL receptor (LDLR) in the liver and thereby contributes to cholesterol homeostasis. PCSK9 is synthesized as a precursor protein that undergoes processing between the prodomain and catalytic domain. This processing is required for PCSK9 to be secreted and to undertake its biological activity. The secreted enzyme is known to bind to the epidermal growth factor- like repeat A (EGF-A) domain of the LDLR. Our goal is to identify compounds that interfere with PCSK9 and the LDLR binding and its ability to participate in the degradation of the LDL receptor. To achieve our goal, we have integrated virtual (computer) screening methods and cell based assays and identified screening hits. Daily administration of one of these compounds to animals that are fed high fat/high cholesterol diet showed significant reduction in cholesterol level. As part of Phase II proposal, we plan to expand and optimize our hits, and confirm the ability of the selected compounds to prevent the LDL receptor degradation, and therefore, decrease the LDL-C level using in vivo studies.